Search - tctmd.com

Displaying 1 - 20 of 410

Sort: Relevancy | Date

News Conference News ACC 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Yael L. Maxwell

April 01, 2026

News Conference News ACC 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Michael O'Riordan

April 01, 2026

News Conference News ACC 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Michael O'Riordan

March 30, 2026

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

News Daily News

Genomics, Lipids, Inflammation at Midlife Predict Future CAD

Caitlin E. Cox

March 25, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Daily News

Lower LDL Levels, Starting Earlier in Life: New ACC/AHA Dyslipidemia Guidelines

Michael O'Riordan

March 13, 2026

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Daily News

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Michael O'Riordan

January 09, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

Caitlin E. Cox

December 01, 2025

News Opinion CV Team Dispatch

November 2025 Dispatch for the CV Team

L.A. McKeown

November 24, 2025

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

News Daily News

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Yael L. Maxwell

November 10, 2025

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Caitlin E. Cox

November 08, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

Advertisement

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Genomics, Lipids, Inflammation at Midlife Predict Future CAD

What’s Going to Be Hot at ACC 2026

Lower LDL Levels, Starting Earlier in Life: New ACC/AHA Dyslipidemia Guidelines

Side Effects of Statins Might Be Overstated: CTT Collaboration

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Year in Review: Top Prevention Stories of 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

TCTMD’s Top 10 Most Popular Stories for November 2025

November 2025 Dispatch for the CV Team

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content